Breast Cancer

Elderly breast cancer patients tolerated idarubicin at the dose of 5 mg/day for 21 consecutive days

Published in Cancer Weekly, July 4th, 2006

Elderly breast cancer patients tolerated idarubicin (IDA) at the dose of 5 mg/day for 21 consecutive days but did not exhibit an improvement in efficacy.

According to a recent report, researchers in Italy conducted a study "to determine if protracted low-dose oral IDA, feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. Elderly women ({{>=}}65 years) with metastatic breast carcinoma were treated with 7.5 mg/day for 21 consecutive days, every 4 weeks."

"After the first 14 patients, due to excessive toxicity, the protocol was amended to 5 mg/day,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry